Current Report Filing (8-k)
13 November 2018 - 10:23PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 13, 2018
IMPRIMIS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35814
|
|
45-0567010
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
12264
El Camino Real, Suite 350
|
|
|
San
Diego, CA
|
|
92130
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 704-4040
N/A
|
(Former
name or former address if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
2.02 Results of Operations and Financial Condition.
On
November 13, 2018, Imprimis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial
results for the quarter ended September 30, 2018. The press release is being furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The
information furnished under this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to
be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02, including Exhibit 99.1,
shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except to the extent it is specifically incorporated by reference but regardless of any general incorporation language in such
filing.
The
information furnished under this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to
constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information
or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any
obligation to update such information or exhibit in the future.
Item
9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Imprimis Pharmaceuticals, Inc.
|
|
|
Date:
November 13, 2018
|
By:
|
/s/
Andrew R. Boll
|
|
Name:
|
Andrew
R. Boll
|
|
Title:
|
Chief
Financial Officer
|
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ): 0 Nachrichtenartikel
Weitere Imprimis Pharmaceuticals, Inc. News-Artikel